Skip to content

Biohaven BHVN Free cash flow

Free cash flow at other companies

Eli Lilly logo
Eli LillyLLY
$3.01B+1,828%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-$89.03M-44.3%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
-$13.15M+36.0%
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
-$132.78M-66.5%
uniQure logo
uniQureQURE
-$38.38M+13.2%
Roivant Sciences logo
Roivant SciencesROIV

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%

Valuation

See full
Market cap$2.23B-48.1%
Enterprise value$2.23B-46.3%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Calculated from Biohaven’s reported figures.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's free cash flow?
Biohaven (BHVN) reported free cash flow of -$149.92M in Q1 2026.
How has Biohaven's free cash flow changed year-over-year?
Biohaven's free cash flow increased by 9.5% year-over-year, from -$165.59M to -$149.92M.
What is the long-term trend for Biohaven's free cash flow?
Over 3 years (2022 to 2025), Biohaven's free cash flow has grown at a 26.2% compound annual growth rate (CAGR), from -$303.76M to -$610.15M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.